Literature DB >> 27301264

Time Course and Factors Correlating With Ventricular Tachyarrhythmias After Introduction of Steroid Therapy in Cardiac Sarcoidosis.

Masato Segawa1, Koji Fukuda2, Makoto Nakano1, Masateru Kondo1, Hiroyuki Satake1, Michinori Hirano1, Hiroaki Shimokawa1.   

Abstract

BACKGROUND: The time course and factors correlating with ventricular tachyarrhythmias (VTs) after introduction of corticosteroid therapy in patients with cardiac sarcoidosis remain to be elucidated. METHODS AND
RESULTS: We examined 68 consecutive patients with cardiac sarcoidosis in the Tohoku University Hospital from October 1998 to September 2014 (age: 57±11 years old; male:female 18:50) and evaluated VTs after initiation of steroid therapy. VTs were defined as documented ventricular tachycardia or ventricular fibrillation lasting for more than 30 seconds or resulting in cardiovascular collapse, or appropriate implantable cardioverter defibrillator therapy. During a mean follow-up of 5.5 years, 20 out of 68 patients (29%) experienced VTs after initiation of corticosteroid therapy, especially in the first 12 months in 14 patients (70%). A multivariable analysis revealed that positive gallium scintigraphy had a significant correlation with VTs (hazard ratio, 11.33; 95% confidence interval, 3.22-39.92; P<0.001), in addition to reduced left ventricular ejection fraction (hazard ratio, 0.94; 95% confidence interval, 0.90-0.97; P=0.001). Furthermore, electrical storm was noted in 10 patients (14.7%), 8 within the first 12 months of treatment, whereas the recurrence of electric storm was relatively less.
CONCLUSIONS: These results indicate that VTs and electric storm frequently occur in the first 12 months after initiation of corticosteroid therapy, presumably because of inflammatory conditions, and that the positive gallium scintigraphy is a significant and independent predictor of VTs. The present findings may be useful to further improve the management of VTs in patients with cardiac sarcoidosis.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  inflammation; prevalence; risk factor; sarcoidosis; ventricular fibrillation

Mesh:

Substances:

Year:  2016        PMID: 27301264     DOI: 10.1161/CIRCEP.115.003353

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  14 in total

Review 1.  Cardiac Sarcoidosis.

Authors:  Pranav Mankad; Brian Mitchell; David Birnie; Jordana Kron
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

2.  Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis.

Authors:  Felipe Kazmirczak; Ko-Hsuan Amy Chen; Selcuk Adabag; Lisa von Wald; Henri Roukoz; David G Benditt; Osama Okasha; Afshin Farzaneh-Far; Jeremy Markowitz; Prabhjot S Nijjar; Pratik S Velangi; Maneesh Bhargava; David Perlman; Sue Duval; Mehmet Akçakaya; Chetan Shenoy
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-08-21

3.  Controversies in the Treatment of Cardiac Sarcoidosis.

Authors:  Ogugua Ndili Obi; Elyse E Lower; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

Review 4.  How to manage various arrhythmias and sudden cardiac death in the cardiovascular intensive care.

Authors:  Yoshinori Kobayashi
Journal:  J Intensive Care       Date:  2018-04-11

Review 5.  Management of Arrhythmias Associated with Cardiac Sarcoidosis.

Authors:  Hirotaka Yada; Kyoko Soejima
Journal:  Korean Circ J       Date:  2019-02       Impact factor: 3.243

6.  Resolution of new left bundle branch block and ventricular tachycardia with immunosuppressive therapy in a patient with cardiac sarcoidosis.

Authors:  Aatish Garg; Huzaefah Syed; Santosh K Padala; Kenneth A Ellenbogen; Jordana Kron
Journal:  HeartRhythm Case Rep       Date:  2019-04-29

Review 7.  Strategies for Managing Arrhythmias in Patients with Cardiac Sarcoidosis.

Authors:  Kent R Nilsson; Venkateshwar Polsani; Thomas F Deering
Journal:  J Innov Card Rhythm Manag       Date:  2019-01-15

8.  Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis.

Authors:  David G Rosenthal; Purvi Parwani; Tyler O Murray; Bradley J Petek; Bryan S Benn; Teresa De Marco; Edward P Gerstenfeld; Munir Janmohamed; Liviu Klein; Byron K Lee; Joshua D Moss; Melvin M Scheinman; Henry H Hsia; Van Selby; Laura L Koth; Miguel H Pampaloni; Julie Zikherman; Vasanth Vedantham
Journal:  J Am Heart Assoc       Date:  2019-09-06       Impact factor: 5.501

Review 9.  Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.

Authors:  Nisha A Gilotra; Jan M Griffin; Noelle Pavlovic; Brian A Houston; Jessica Chasler; Colleen Goetz; Jonathan Chrispin; Michelle Sharp; Edward K Kasper; Edward S Chen; Ron Blankstein; Leslie T Cooper; Emer Joyce; Farooq H Sheikh
Journal:  J Card Fail       Date:  2021-07-11       Impact factor: 5.712

Review 10.  Clinical Features and Diagnosis of Cardiac Sarcoidosis.

Authors:  Claudio Tana; Cesare Mantini; Iginio Donatiello; Luciano Mucci; Marco Tana; Fabrizio Ricci; Francesco Cipollone; Maria Adele Giamberardino
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.